Company / Accounts Receivable
ENANTA PHARMACEUTICALS INC Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$6.9M
FY2025
5-year range
$6.6M / $23.6M
FY2021-FY2025
Trend
+3.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable returned to growth in FY2025 after 3 years of decline, reaching $7M.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of -21.8%.
Declined from $9M to $7M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -30.3%
- 5-Year CAGR
- -21.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -21.8%, indicating a declining trend.
- In FY2025, accounts receivable increased 3.6% year-over-year.
- Peak accounts receivable was recorded in FY2018.
- Lowest accounts receivable in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.9M | +3.6% |
| FY2024 | $6.6M | -22.8% |
| FY2023 | $8.6M | -57.6% |
| FY2022 | $20.3M | -13.8% |
| FY2021 | $23.6M | +0.4% |
| FY2020 | $23.5M | -54.2% |
| FY2019 | $51.3M | -23.6% |
| FY2018 | $67.2M | +533.2% |
| FY2017 | $10.6M | -17.3% |
| FY2016 | $12.8M | -16.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026